Theranostic properties of a survivin-directed molecular beacon in human melanoma cells

PLoS ONE

Volumn 9, Issue 12, 2014, Pages

  Carpi, Sara ^a   Fogli, Stefano ^a   Giannetti, Ambra ^b   Adinolfi, Barbara ^a   Tombelli, Sara ^b   Da Pozzo, Eleonora ^a   Vanni, Alessia ^a   Martinotti, Enrica ^a   Martini, Claudia ^a   Breschi, Maria Cristina ^a   Pellegrino, Mario ^a   Nieri, Paola ^a   Baldini, Francesco ^b  

^a UNIVERSITY OF PISA   (Italy)

^b IFAC CNR   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOCETAXEL; MESSENGER RNA; OLIGODEOXYNUCLEOTIDE; SURVIVIN; ANTINEOPLASTIC AGENT; BIRC5 PROTEIN, HUMAN; INHIBITOR OF APOPTOSIS PROTEIN; OLIGONUCLEOTIDE PROBE;

APOPTOSIS; ARTICLE; CELL CULTURE; CONCENTRATION RESPONSE; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; CYTOPLASM; DNA FRAGMENTATION; DOWN REGULATION; DRUG MECHANISM; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; IN VITRO STUDY; MELANOMA CELL LINE; MITOCHONDRIAL MEMBRANE POTENTIAL; MOLECULAR BEACON; MOLECULAR IMAGING; PROTEIN EXPRESSION; PROTEIN TARGETING; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; BIOSYNTHESIS; DRUG EFFECTS; ENZYME SPECIFICITY; GENE EXPRESSION REGULATION; GENETICS; MELANOMA; METABOLISM; OLIGONUCLEOTIDE PROBE; PATHOLOGY; THERAPEUTIC USE; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; DNA FRAGMENTATION; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MELANOMA; MEMBRANE POTENTIAL, MITOCHONDRIAL; OLIGONUCLEOTIDE PROBES; RNA, MESSENGER; SUBSTRATE SPECIFICITY;

EID: 84918497318     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0114588     Document Type: Article

References (42)

1. World Health Organization. Skin cancers. Available: http://who.int/uv/faq/skincancer/en/index1.html. Accessed june 9, 2014
2. Hartman ML, Czyz M (2013) Anti-apoptotic proteins on guard of melanoma cell survival. Cancer Lett 331: 24-34.
3. Mckenzie JA, Grossman D (2012) Role of the apoptotic and mitotic regulator survivin in melanoma. Anticancer Res 32: 397-404.
4. Altieri DC, Grossman D (2001) Drug Resistance in Melanoma: Mechanisms, Apoptosis, and New Potential Therapeutic Targets. Cancer Metastasis Rev 20: 3-11.
5. Sullivan RJ, Flaherty KT (2014) Major therapeutic developments and current challenges in advanced melanoma. Br J Dermatol 170: 36-44.
6. Ambrosini G, Adida C, Altieri DC (1997) A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat med 3: 917-21.
7. Altieri DC (2008) Survivin, cancer netwoks and pathway-directed drug discovery. Nat Rev Cancer 8: 61-70.
8. Groner B. Weiss A (2014) Targeting survivin in cancer: novel drug development approaches. BioDrugs 28: 27-39.
9. Mita AC, Mita MM, Nawrocki ST, Giles FJ (2008) Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res 14: 5000-5005.
10. Altieri DC (2001) The molecular basis and potential role of survivin in cancer diagnosis and therapy. Trends Mol Med 7: 542-547.
11. Grossman D, McNiff JM, Li F, Altieri DC (1999) Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. J Invest Dermatol 113: 1076-1081.
12. Hartman MM, Czyz M (2013) Anti-apoptotic proteins on guard of melanoma cell survival. Cancer Lett 331: 24-34.
13. Takeuchi H, Morton DL, Elashoff D, Hoon DSB (2005) Survivin expression by metastatic melanoma predicts poor disease outcome in patients receiving adjuvant polyvalent vaccine. Int J Cancer 117: 1032-8.
14. Chen N, Gong J, Chen X, Meng W, Huang Y, et al. (2009) Caspases and inhibitor of apoptosis proteins in cutaneous and mucosal melanoma: expression profile and clinicopathologic significance. Hum Pathol 40: 950-956.
15. Wang Q, Chen L, Long Y, Tian H, Wu J (2013) Molecular beacons of xeno-nucleic acid for detecting nucleic acid. Theranostics 3: 395-408.
16. Kolpashchikov DM (2012) An elegant biosensor molecular beacon probe: challenges and recent solutions. Scientifica 2012: 1-17.
17. Santangelo P, Nitin N, Bao G (2006) Nanostructured probes for RNA detection in living cells. Ann biomed eng 34: 39-50.
18. Giannetti A, Tombelli S, Baldini F (2013) Oligonucleotide optical switches for intracellular sensing. Anal Bioanal Chem 405: 6181-6196.
19. Han SX, Jia X, Ma JL, Zhu Q (2013) Molecular beacons: a novel optical diagnostic tool. Arch Immunol Ther Exp 61: 139-148.
20. Nitin N, Santangelo PJ, Kim G, Nie S, Bao G (2004) Peptide linked molecular beacons for efficient delivery and rapid mRNA detection in living cells. Nucleic Acids Res 32: 58.
21. Neri T, Cordazzo C, Carmazzi Y, Petrini S, Balìa C, et al. (2012) Effects of peroxisome proliferator-activated receptor-γ agonists on the generation of microparticles by monocytes/macrophages. Cardiovasc Res 94: 537-44.
22. Zhou L, Chen Z, Wang F, Yang X, Zhang B (2013) Multifunctional triblock co-polymer mP3/4HB-b-PEG-b-lPEI for efficient intracellular siRNA delivery and gene silencing. Acta Biomater 9(4):6019-31.
23. Li G, Chang H, Zhai YP, Xu W (2013) Targeted silencing of inhibitors of apoptosis proteins with siRNAs: a potential anti-cancer strategy for hepatocellular carcinoma. Asian Pac J Cancer Prev 14(9):4943-52.
24. Ryan MB, O'Donovan N, Duffy MJ (2009) Survivin: a new target for anti-cancer therapy. Cancer Treat Rev 35: 553-562.
25. Sinha R, Kim GJ, Nie S, Shin DM (2006) Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery. Mol Cancer Ther 5: 1909-17.
26. Cheung CHA, Huang CC, Tsai FY, Lee JYC, Cheng SM, et al. (2013) Survivin-biology and potential as a therapeutic target in oncology. Onco Targets Ther 6: 1453-1462.
27. McKenzie JA, Liu T, Goodson AG, Grossman D (2010) Survivin enhances motility of melanoma cells by supporting Akt activation and {alpha}5 integrin upregulation. Cancer Res 70: 7927-7937.
28. McKenzie JA, Liu T, Jung JY, Jones BB, Ekiz HA, et al. (2013) Survivin promotion of melanoma metastasis requires upregulation of a5 integrin. Carcinogenesis 34: 2137-2144.
29. Santangelo PJ, Nix B, Tsourkas A, Bao G (2004) Dual FRET molecular beacons for mRNA detection in living cells. Nucleic Acids Res 32: 57.
30. Peng XH, Cao ZH, Xia JT, Carlson GW, Lewis MM, et al. (2005) Real-time detection of gene expression in cancer cells using molecular beacon imaging: new strategies for cancer research. Cancer Res 65: 1909-17.
31. Dohi T, Beltrami E, Wall NR, Plescia J, Altieri DC (2004) Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis. J Clin Invest 114: 1117-1127.
32. Vong Q, Cao K, Li H, Iglesias P, Zheng Y (2005) Chromosome alignement and segregation regulated by ubiquitination of survivin. Science 310: 1499-1505.
33. Szafer-Glusman E, Fuller M, Giansanti M (2011) Role of survivin in cytokinesis revealed by a separation of function allele. Mol Biol Cell 20: 3779-2790.
34. Carrasco RA, Stamm B, Marcusson E, Sandusky G, Iversen P, et al. (2011) Antisense inhibition of survivin expression as a cancer therapeutic. Mol Cancer Ther 10: 221-232.
35. Pennati M, Folini M, Zaffaroni N (2008) Targeting survivin in cancer therapy Expert Opin Ther Targets 124: 463-476.
36. Yamanaka K, Nakahara T, Yamauchi T, Kita A, Takeuchi M, et al. (2011) Antitumor activity of YM155, a selective small-molecule survivin suppressant, alone and in combination with docetaxel in human malignant melanoma models. Clin Cancer Res 17: 5423-5431.
37. Li H, Niederkon JY, Neelam S, Alizadeh H (2006) Downregulation of survivin expression enhances sensitivity of cultured uveal melanoma cells to cisplatin treatment. Exp Eye Res 83: 176-182.
38. Yang H, Fu JH, Hu Y, Huang WZ, Zheng B, et al. (2008) Influence of siRNA targetingsurvivin on chemosensitivity of H460/cDDP lung cancer cells. J Int Med Res 36: 734-747.
39. Kaneko N, Yamanaka K, Kita A, Tabata K, Akabane T, et al. (2013) Synergistic antitumor activities of sepantronium bromide (YM155), a survivin suppressant, in combination with microtubule-targeting agents in triple-negative breast cancer cells. Biol Pharm Bull 36: 1921-7.
40. Zheng W, Chen H, Yuan S, Wu L, Zhang W, et al. (2012) Overexpression of bIII-tubulin and survivin associated with drug resistance to docetaxel-based chemotherapy in advanced gastric cancer. J Buon 17: 284-290.
41. Ikeguchi M, Liu J, Kaibara N (2002) Expression of survivin mRNA and protein in gastric cancer cell line (MKN-45) during cisplatin treatment. Apoptosis 1: 23-9.
42. Shi W, Li J, Bao Q, Wu J, Ge L, Zhu L, et al. (2014) Survivin mRNA expression in blood as a predictor of the response to EGFR-tyrosine kinase inhibitors and prognosis in patients with non-small cell lung cancer. Med Oncol 31: 893.